Purpose: Topotecan, administered intravenously, is active in small-cell lung cancer (SCLC).
In this study, the comparability of oral topotecan to IV topotecan was investigated. Patients …

Brain is the most common site of metastatic spread in small-cell lung cancer (SCLC).
Approximately 10% of SCLC patients have brain metastases (BM) already at diagnosis and …

Topoisomerase I (topo-I) inhibitors are a new class of anticancer agents with a mechanism
of action aimed at interrupting DNA replication in cancer cells, the result of which is cell …

Objective This study was conducted to assess the activity and toxicity of gemcitabine in
patients with resistant small-cell lung cancer (SCLC) Patients and methods Forty-one …

Purpose The activity and toxicity of paclitaxel plus carboplatin combination in patients with
disease progression after initial chemotherapy for small-cell lung cancer (SCLC) was …

目的: 观察国产拓扑替康单药二线治疗复发性小细胞肺癌(small cell lung cancer, SCLC)
和与顺铂联合方案治疗初治SCLC 的疗效及毒性. 方法: 采用多中心开放式研究方法, 在100 …

Chemotherapy is the treatment of choice in metastatic stage of small-cell lung cancer
(SCLC). Radiation therapy, surgery and other forms of therapy are only included in special …

Objective tumor responses and survival rates with standard chemotherapy options for small-
cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC) have been disappointing …

When, in 1971, President Nixon signed the National Cancer Act in the USA, there was much
optimism about the possibility of 'conquering cancer'and ending the burden of suffering and …

Purpose: To evaluate the feasibility and pharmacology of intraperitoneal (IP) topotecan.
Patients and methods: Fifteen patients with recurrent ovarian cancer in a phase I trial were …